Jean-Paul Pirnay

List of Publications by Year
in descending order

107	6,332	53789 45	74160 75
papers	citations	h-index	g-index

111	111	111	5474
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Recent progress toward the implementation of phage therapy in Western medicine. FEMS Microbiology Reviews, 2022, 46, .	8.6	50
2	European regulatory aspects of phage therapy: magistral phage preparations. Current Opinion in Virology, 2022, 52, 24-29.	5.4	32
3	Combination of pre-adapted bacteriophage therapy and antibiotics for treatment of fracture-related infection due to pandrug-resistant Klebsiella pneumoniae. Nature Communications, 2022, 13, 302.	12.8	97
4	Parallel evolution of Pseudomonas aeruginosa phage resistance and virulence loss in response to phage treatment in vivo and in vitro. ELife, 2022, 11, .	6.0	31
5	Screening of Anorectal and Oropharyngeal Samples Fails to Detect Bacteriophages Infecting Neisseria gonorrhoeae. Antibiotics, 2022, 11, 268.	3.7	1
6	Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review. Lancet Infectious Diseases, The, 2022, 22, e208-e220.	9.1	125
7	In Vitro and In Vivo Assessments of Two Newly Isolated Bacteriophages against an ST13 Urinary Tract Infection Klebsiella pneumoniae. Viruses, 2022, 14, 1079.	3.3	6
8	In Vitro Techniques and Measurements of Phage Characteristics That Are Important for Phage Therapy Success. Viruses, 2022, 14, 1490.	3.3	34
9	Bacteriophages: it's a medicine, Jim, but not as we know it. Lancet Infectious Diseases, The, 2021, 21, 309-311.	9.1	32
10	A Case of Phage Therapy against Pandrug-Resistant Achromobacter xylosoxidans in a 12-Year-Old Lung-Transplanted Cystic Fibrosis Patient. Viruses, 2021, 13, 60.	3.3	65
11	Genomics of an endemic cystic fibrosis Burkholderia multivorans strain reveals low within-patient evolution but high between-patient diversity. PLoS Pathogens, 2021, 17, e1009418.	4.7	11
12	Evaluation of the Stability of Bacteriophages in Different Solutions Suitable for the Production of Magistral Preparations in Belgium. Viruses, 2021, 13, 865.	3.3	34
13	Variant Analysis of SARS-CoV-2 Genomes from Belgian Military Personnel Engaged in Overseas Missions and Operations. Viruses, 2021, 13, 1359.	3.3	6
14	Evaluating Diagnostic Accuracy of Saliva Sampling Methods for Severe Acute Respiratory Syndrome Coronavirus 2 Reveals Differential Sensitivity and Association with Viral Load. Journal of Molecular Diagnostics, 2021, 23, 1249-1258.	2.8	7
15	Bacteriophage Therapy for Difficult-to-Treat Infections: The Implementation of a Multidisciplinary Phage Task Force (The PHAGEFORCE Study Protocol). Viruses, 2021, 13, 1543.	3.3	21
16	A Case of In Situ Phage Therapy against Staphylococcus aureus in a Bone Allograft Polymicrobial Biofilm Infection: Outcomes and Phage-Antibiotic Interactions. Viruses, 2021, 13, 1898.	3.3	18
17	A Design of Experiment Approach to Optimize Spray-Dried Powders Containing Pseudomonas aeruginosaPodoviridae and Myoviridae Bacteriophages. Viruses, 2021, 13, 1926.	3.3	7
18	Successful case of adjunctive intravenous bacteriophage therapy to treat left ventricular assist device infection. Journal of Infection, 2021, 83, e1-e3.	3.3	14

#	Article	IF	Citations
19	Bacteriophage Rescue Therapy of a Vancomycin-Resistant Enterococcus faecium Infection in a One-Year-Old Child following a Third Liver Transplantation. Viruses, 2021, 13, 1785.	3.3	29
20	Epidemiology and etiology of blood stream infections in a Belgian burn wound center. Acta Clinica Belgica, 2021, , 1-7.	1.2	3
21	In Vitro Evaluation of the Therapeutic Potential of Phage VA7 against Enterotoxigenic Bacteroides fragilis Infection. Viruses, 2021, 13, 2044.	3.3	3
22	Phage Therapy. WikiJournal of Medicine, 2021, 8, 4.	1.0	1
23	Bacteriophage Therapy for the Prevention and Treatment of Fracture-Related Infection Caused by Staphylococcus aureus: a Preclinical Study. Microbiology Spectrum, 2021, 9, e0173621.	3.0	15
24	The Unique Role That WHO Could Play in Implementing Phage Therapy to Combat the Global Antibiotic Resistance Crisis. Frontiers in Microbiology, 2020, 11, 1982.	3.5	6
25	Study of a SARS-CoV-2 Outbreak in a Belgian Military Education and Training Center in Maradi, Niger. Viruses, 2020, 12, 949.	3.3	19
26	Characterization of Salmonella Isolates from Various Geographical Regions of the Caucasus and Their Susceptibility to Bacteriophages. Viruses, 2020, 12, 1418.	3.3	15
27	Phage Therapy in the Year 2035. Frontiers in Microbiology, 2020, 11, 1171.	3.5	58
28	Prevalence of Anaplasma phagocytophilum in humans in Belgium for the period 2013â€“2016.. Acta Clinica Belgica, 2019, 74, 280-285.	1.2	4
29	Development of a qPCR platform for quantification of the five bacteriophages within bacteriophage cocktail 2 (BFC2). Scientific Reports, 2019, 9, 13893.	3.3	19
30	Bacteriophage Application for Difficult-to-treat Musculoskeletal Infections: Development of a Standardized Multidisciplinary Treatment Protocol. Viruses, 2019, 11, 891.	3.3	98
31	Processing Phage Therapy Requests in a Brussels Military Hospital: Lessons Identified. Viruses, 2019, 11, 265.	3.3	62
32	Clinical application of bacteriophages in Europe. Microbiology Australia, 2019, 40, 8.	0.4	16
33	Production of Phage Therapeutics and Formulations: Innovative Approaches. , 2019, , 3-41.		2
34	Phage Therapy in Europe: Regulatory and Intellectual Property Protection Issues. , 2019, , 363-377.		2
35	Bacteriophage Production in Compliance with Regulatory Requirements. Methods in Molecular Biology, 2018, 1693, 233-252.	0.9	34
36	Guidelines to Compose an Ideal Bacteriophage Cocktail. Methods in Molecular Biology, 2018, 1693, 99-110.	0.9	78

#	Article	IF	Citations
37	Biological tests carried out on serum/plasma samples from donors of human body material for transplantation: Belgian experience and practical recommendations. Cell and Tissue Banking, 2018, 19, 681-695.	1.1	4
38	Silk Route to the Acceptance and Re-Implementation of Bacteriophage Therapyâ€"Part II. Antibiotics, 2018, 7, 35.	3.7	46
39	The Magistral Phage. Viruses, 2018, 10, 64.	3.3	232
40	Selection of Potential Therapeutic Bacteriophages that Lyse a CTX-M-15 Extended Spectrum Î²-Lactamase Producing Salmonella enterica Serovar Typhi Strain from the Democratic Republic of the Congo. Viruses, 2018, 10, 172.	3.3	22
41	Pseudomonads from wild free-living sea turtles in PrÃncipe Island, Gulf of Guinea. Ecological Indicators, 2017, 81, 260-264.	6.3	4
42	Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injuryâ€"a case report. Critical Care, 2017, 21, 129.	5.8	185
43	Application of bacteriophages. Microbiology Australia, 2017, 38, 63.	0.4	18
44	Stability of bacteriophages in burn wound care products. PLoS ONE, 2017, 12, e0182121.	2.5	47
45	The Developing World Urgently Needs Phages to Combat Pathogenic Bacteria. Frontiers in Microbiology, 2016, 7, 882.	3.5	63
46	Molecular Epidemiology and Clinical Impact of Acinetobacter calcoaceticus-baumannii Complex in a Belgian Burn Wound Center. PLoS ONE, 2016, 11, e0156237.	2.5	39
47	Antimicrobial resistance and genomic rep-PCR fingerprints of Pseudomonas aeruginosa strains from animals on the background of the global population structure. BMC Veterinary Research, 2016, 13, 58.	1.9	14
48	Silk route to the acceptance and reâ€implementation of bacteriophage therapy. Biotechnology Journal, 2016, 11, 595-600.	3.5	54
49	Preâ€adapting parasitic phages to a pathogen leads to increased pathogen clearance and lowered resistance evolution with Pseudomonas aeruginosa cystic fibrosis bacterial isolates. Journal of Evolutionary Biology, 2016, 29, 188-198.	1.7	83
50	Bacteriophage therapy: Fast-forward to the past lessons identified from the advanced therapy regulation. Burns, 2016, 42, 11-12.	1.9	7
51	A bacteriophage journey at the European Medicines Agency. FEMS Microbiology Letters, 2016, 363, fnv225.	1.8	67
52	Access to bacteriophage therapy: discouraging experiences from the human cell and tissue legal framework. FEMS Microbiology Letters, 2016, 363, fnv241.	1.8	11
53	Increase of efflux-mediated resistance in Pseudomonas aeruginosa during antibiotic treatment in patients suffering from nosocomial pneumonia. International Journal of Antimicrobial Agents, 2016, 47, 77-83.	2.5	20
54	Access to human tissues for research and product development. EMBO Reports, 2015, 16, 557-562.	4.5	28

#	Article	IF	Citations
55	Clinical utilization of genomics data produced by the international Pseudomonas aeruginosa consortium. Frontiers in Microbiology, 2015, 6, 1036.	3.5	144
56	Recellularizing of human acellular dermal matrices imaged by high-definition optical coherence tomography. Experimental Dermatology, 2015, 24, 349-354.	2.9	4
57	The Widespread Multidrug-Resistant Serotype O12 Pseudomonas aeruginosa Clone Emerged through Concomitant Horizontal Transfer of Serotype Antigen and Antibiotic Resistance Gene Clusters. MBio, 2015, 6, e01396-15.	4.1	47
58	Quality and Safety Requirements for Sustainable Phage Therapy Products. Pharmaceutical Research, 2015, 32, 2173-2179.	3.5	176
59	Correlation between cytotoxicity induced byPseudomonas aeruginosaclinical isolates from acute infections and IL-1Î² secretion in a model of human THP-1 monocytes. Pathogens and Disease, 2015, 73, ftv049.	2.0	16
60	In the Name of Quality and Safety: Commercialization of Human Cells and Tissues. , 2015, , 265-284.		0
61	O serotypeâ€independent susceptibility of Pseudomonas aeruginosa to lectinâ€like pyocins. MicrobiologyOpen, 2014, 3, 875-884.	3.0	18
62	Real-time three-dimensional imaging of epidermal splitting and removal by high-definition optical coherence tomography. Experimental Dermatology, 2014, 23, 725-730.	2.9	9
63	Taking Bacteriophage Therapy Seriously: A Moral Argument. BioMed Research International, 2014, 2014, 1-8.	1.9	31
64	Effectiveness of bacteriophages in the sputum of cystic fibrosis patients. Clinical Microbiology and Infection, 2014, 20, O983-O990.	6.0	58
65	Characterization of Newly Isolated Lytic Bacteriophages Active against Acinetobacter baumannii. PLoS ONE, 2014, 9, e104853.	2.5	80
66	Call for a Dedicated European Legal Framework for Bacteriophage Therapy. Archivum Immunologiae Et Therapiae Experimentalis, 2014, 62, 117-129.	2.3	71
67	Art-175 Is a Highly Efficient Antibacterial against Multidrug-Resistant Strains and Persisters of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2014, 58, 3774-3784.	3.2	152
68	Engineered Endolysin-Based â€œArtilysinsâ€•To Combat Multidrug-Resistant Gram-Negative Pathogens. MBio, 2014, 5, e01379-14.	4.1	279
69	Experimental phage therapy of burn wound infection: difficult first steps. International Journal of Burns and Trauma, 2014, 4, 66-73.	0.2	111
70	Cleanrooms and tissue banking how happy I could be with either GMP or GTP?. Cell and Tissue Banking, 2013, 14, 571-578.	1.1	5
71	Evaluation of oprI and oprL genes as molecular markers for the genus Pseudomonas and their use in studying the biodiversity of a small Belgian River. Research in Microbiology, 2013, 164, 254-261.	2.1	30
72	Developing an international Pseudomonas aeruginosa reference panel. MicrobiologyOpen, 2013, 2, 1010-1023.	3.0	94

#	Article	IF	Citations
73	Business oriented EU human cell and tissue product legislation will adversely impact Member Statesâ€™ health care systems. Cell and Tissue Banking, 2013, 14, 525-560.	1.1	46
74	Paving a regulatory pathway for phage therapy. EMBO Reports, 2013, 14, 951-954.	4.5	32
75	Stability of Staphylococcus aureus Phage ISP after Freeze-Drying (Lyophilization). PLoS ONE, 2013, 8, e68797.	2.5	99
76	Effects of Sequential and Simultaneous Applications of Bacteriophages on Populations of Pseudomonas aeruginosa In Vitro and in Wax Moth Larvae. Applied and Environmental Microbiology, 2012, 78, 5646-5652.	3.1	139
77	Introducing yesterdayâ€™s phage therapy in todayâ€™s medicine. Future Virology, 2012, 7, 379-390.	1.8	80
78	Beware of the commercialization of human cells and tissues: situation in the European Union. Cell and Tissue Banking, 2012, 13, 487-498.	1.1	11
79	Optimizing the European Regulatory Framework for Sustainable Bacteriophage Therapy in Human Medicine. Archivum Immunologiae Et Therapiae Experimentalis, 2012, 60, 161-172.	2.3	67
80	Evaluation of a microbiological screening and acceptance procedure for cryopreserved skin allografts based on 14Âday cultures. Cell and Tissue Banking, 2012, 13, 287-295.	1.1	24
81	Glycerol treatment as recovery procedure for cryopreserved human skin allografts positive for bacteria and fungi. Cell and Tissue Banking, 2012, 13, 1-7.	1.1	17
82	Feeder layer- and animal product-free culture of neonatal foreskin keratinocytes: improved performance, usability, quality and safety. Cell and Tissue Banking, 2012, 13, 175-189.	1.1	45
83	Selection and Characterization of a Candidate Therapeutic Bacteriophage That Lyses the Escherichia coli O104:H4 Strain from the 2011 Outbreak in Germany. PLoS ONE, 2012, 7, e52709.	2.5	48
84	Actin dynamics regulate immediate PAR-2-dependent responses to acute epidermal permeability barrier abrogation. Journal of Dermatological Science, 2011, 61, 101-109.	1.9	12
85	Schistosomiasis in Belgian Military Personnel Returning From the Democratic Republic of Congo. Military Medicine, 2011, 176, 1341-1346.	0.8	18
86	Microbiological and Molecular Assessment of Bacteriophage ISP for the Control of Staphylococcus aureus. PLoS ONE, 2011, 6, e24418.	2.5	92
87	Potential release of aluminum and other metals by food-grade aluminum foil used for skin allograft cryo preservation. Cell and Tissue Banking, 2011, 12, 241-246.	1.1	2
88	The Phage Therapy Paradigm: PrÃªt-Ã-Porter or Sur-mesure?. Pharmaceutical Research, 2011, 28, 934-937.	3.5	249
89	Human cells and tissues: the need for a global ethical framework. Bulletin of the World Health Organization, 2010, 88, 870-872.	3.3	15
90	In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy. International Journal of Antimicrobial Agents, 2010, 36, 513-522.	2.5	72

#	Article	IF	Citations
91	Pseudomonas aeruginosa Population Structure Revisited. PLoS ONE, 2009, 4, e7740.	2.5	223
92	Comparison of the sensitivity of culture, PCR and quantitative real-time PCR for the detection of Pseudomonas aeruginosain sputum of cystic fibrosis patients. BMC Microbiology, 2009, 9, 244.	3.3	56
93	Survey of Pseudomonas aeruginosa and its phages: de novo peptide sequencing as a novel tool to assess the diversity of worldwide collected viruses. Environmental Microbiology, 2009, 11, 1303-1313.	3.8	32
94	Distribution and evolution of ferripyoverdine receptors in Pseudomonas aeruginosa. Environmental Microbiology, 2009, 11, 2123-2135.	3.8	54
95	Quality-Controlled Small-Scale Production of a Well-Defined Bacteriophage Cocktail for Use in Human Clinical Trials. PLoS ONE, 2009, 4, e4944.	2.5	391
96	European regulatory conundrum of phage therapy. Future Microbiology, 2007, 2, 485-491.	2.0	81
97	Global Pseudomonas aeruginosa biodiversity as reflected in a Belgian river. Environmental Microbiology, 2005, 7, 969-980.	3.8	149
98	FpvB, an alternative type I ferripyoverdine receptor of Pseudomonas aeruginosa. Microbiology (United) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.8	164
99	Seoul hantavirus in Europe: first demonstration of the virus genome in wild Rattus norvegicus captured in France. European Journal of Clinical Microbiology and Infectious Diseases, 2004, 23, 711-7.	2.9	64
100	No easy way to exterminate â€˜superbugsâ€™ at the dawn of the third millennium. Expert Review of Anti-Infective Therapy, 2003, 1, 523-525.	4.4	2
101	Molecular Epidemiology of Pseudomonas aeruginosa Colonization in a Burn Unit: Persistence of a Multidrug-Resistant Clone and a Silver Sulfadiazine-Resistant Clone. Journal of Clinical Microbiology, 2003, 41, 1192-1202.	3.9	151
102	Identification of new, conserved, non-ribosomal peptide synthetases from fluorescent pseudomonads involved in the biosynthesis of the siderophore pyoverdine. Molecular Microbiology, 2002, 45, 1673-1685.	2.5	118
103	Analysis of the Pseudomonas aeruginosa oprD gene from clinical and environmental isolates. Environmental Microbiology, 2002, 4, 872-882.	3.8	122
104	Pseudomonas aeruginosa displays an epidemic population structure. Environmental Microbiology, 2002, 4, 898-911.	3.8	106
105	Quantitation of Pseudomonas aeruginosa in wound biopsy samples: from bacterial culture to rapid â€˜real-timeâ€™ polymerase chain reaction. Critical Care, 2000, 4, 255-61.	5.8	48
106	Analysis of epidemic Pseudomonas aeruginosa isolated by isoelectric focusing of pyoverdine and RAPD-PCR: modern tools for an integrated anti-nosocomial infection strategy in burn wound centres. Burns, 1997, 23, 379-386.	1.9	34
107	HIV transmission by transplantation of allograft skin: a review of the literature. Burns, 1997, 23, 1-5.	1.9	25